Business Wire

FRISS

13.6.2019 07:02:06 CEST | Business Wire | Press release

Share
Greek Insurance Company Eurolife ERB Wins at IMPACT Bite Awards 2019 with FRISS for Automated Fraud Prevention

Eurolife ERB, a Fairfax company, has won the IMPACT BITE (Business IT Excellence) Awards 2019 in the category IT Business Process Improvement, for its AI approach to assess risks and reduce the likelihood of fraud. The IMPACT Bite Awards is open to all companies, across industries, who have successfully integrated IT & tech systems and/or have taken initiatives in the domains of IT & Comms infrastructure that support their business goals. Eurolife ERB entered the competition with their successful implementation of the FRISS solution for automated fraud prevention. Thanks to this solution they lowered their loss ratio, enabled digital transformation and improved their customer experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190612005694/en/

Eurolife ERB, a leading player in the Greek insurance market, has the goal to reduce the risk it faces in cases of fraud involving future indemnities in the car insurance industry. Through the use of Artificial Intelligence, Eurolife ERB, in close cooperation with FRISS, has created a process of automated, more detailed risk assessment control, seeking faster, more complete and safer processing. This provides them with better customer service while contributing significantly to maintaining a net portfolio.

John Kostoglou, CIO of Eurolife ERB: “I’m very proud that we have won this award. It is great to see that our focus on innovation and digital transformation get recognized. For every insurance company the possibility of fraud is very high, in particular for contracts relating to the car industry. With the help of FRISS we are able to detect high risks and fraud in real-time. With this state-of-the art technology we save time and money for our customers.”

Simon Staadegaard, Sales Manager at FRISS, states: “We are delighted to see that our efforts to detect fraud and support honest insurance pay off. The recognition by IMPACT shows that the insurance industry really values the power of our AI solutions that are combined with our expert industry knowledge. The project with Eurolife ERB went smoothly. It was delivered on time and within budget. We look forward to a bright and fraud free future together.”

About Eurolife ERB

Eurolife ERB Insurance Group is a member of Fairfax Financial Holdings Ltd., who, through its subsidiaries, operates in insurances, reinsurance and investments’ management. Eurolife ERB Insurance Group, through its subsidiaries in Greece and Romania, designs, markets and promotes advanced products and services that meet the full range of contemporary insurance needs. Group companies in Greece include Eurolife ERB Life Insurance SA, Eurolife ERB General Insurance SA and ERB Insurance Brokers SA. A leading player in the bancassurance market, the Group has established a broad network of affiliated insurance agents across Greece. Group companies in Romania include Eurolife ERB Asigurari de Viata and Eurolife ERB Asigurari Generale. Eurolife ERB Insurance Group consistently maintains strong earnings levels and capital reserves in excess of European regulatory requirements, so as to always fulfil its responsibilities towards its clientele. Understanding its role in the society, Eurolife ERB Insurance Group is committed to give back to the communities a part of its profits per year. Through its corporate social responsibility program, the Group implements actions: (a) for quality of life and wellness, (b) for the promotion of education and culture, (c) for entrepreneurship and economy, supporting more choices and optimism for the future.

For more information, visit eurolife.gr

About FRISS

FRISS has a 100% focus on automated fraud and risk detection for P&C insurance companies worldwide. The AI-powered detection solutions for underwriting, claims and SIU have already helped 150+ insurers to grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 6 months, with fixed price projects, and realize an ROI within 12 months. The FRISS solutions help to lower the loss ratio, enable profitable portfolio growth, and improve the customer experience. www.friss.com

Contact:

Ruud van Gerwen PR & Product Marketer at FRISS +31 30 767 0352 Ruud.van.gerwen@friss.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release

Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st

Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release

Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an

Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release

Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai

Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release

– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye